<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Novavax Inc. NVAX, -4.13% gained 2.5% in premarket trading on Friday, the day after the company said its experimental COVID-19 vaccine had an 80% efficacy rate in teens. The results stem from a Phase 3 clinical trial that occurred when delta was the most dominant strain of the virus.
...read full article on Market Watch
